|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
JP4886511B2
(ja)
|
2003-07-30 |
2012-02-29 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
|
|
CA2545425C
(en)
*
|
2003-12-03 |
2013-09-24 |
Cytopia Research Pty Ltd |
Azole-based kinase inhibitors
|
|
EP1742935B1
(en)
|
2004-04-13 |
2010-02-24 |
Icagen, Inc. |
Polycyclic pyrazines as potassium ion channel modulators
|
|
US7884109B2
(en)
|
2005-04-05 |
2011-02-08 |
Wyeth Llc |
Purine and imidazopyridine derivatives for immunosuppression
|
|
AU2006254840B2
(en)
|
2005-06-08 |
2012-08-02 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
NZ566021A
(en)
*
|
2005-07-26 |
2011-03-31 |
Vertex Pharma |
Benzimidazoles useful as inhibitors of protein kinases
|
|
PL2848258T3
(pl)
|
2005-10-26 |
2018-06-29 |
Novartis Ag |
Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
|
|
NO20220050A1
(no)
|
2005-11-21 |
2008-08-12 |
Novartis Ag |
Neuroendokrin tumorbehandling
|
|
GB0601744D0
(en)
|
2006-01-27 |
2006-03-08 |
Novartis Ag |
Organic compounds
|
|
US7989459B2
(en)
*
|
2006-02-17 |
2011-08-02 |
Pharmacopeia, Llc |
Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
|
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
EP2001476A4
(en)
|
2006-03-20 |
2010-12-22 |
Synta Pharmaceuticals Corp |
BENZOIMIDAZOLYL-PARAZINE-BASED COMPOUNDS FOR INFLAMMATION USES AND IMMUNE DISORDERS
|
|
AU2007230911A1
(en)
*
|
2006-03-23 |
2007-10-04 |
Synta Pharmaceuticals Corp. |
Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
|
|
TW200831104A
(en)
*
|
2006-10-04 |
2008-08-01 |
Pharmacopeia Inc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
AR063141A1
(es)
|
2006-10-04 |
2008-12-30 |
Pharmacopeia Inc |
Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
|
|
US7902187B2
(en)
*
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
US8193197B2
(en)
|
2006-10-19 |
2012-06-05 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
AU2013273769B2
(en)
*
|
2006-11-15 |
2016-05-12 |
Ym Biosciences Australia Pty Ltd |
Inhibitors of Kinase Activity
|
|
EP2099774A4
(en)
*
|
2006-11-15 |
2010-11-24 |
Ym Biosciences Australia Pty L |
INHIBITORS OF KINASEACTIVITY
|
|
US20080119496A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Pharmacopeia Drug Discovery, Inc. |
7-Substituted Purine Derivatives for Immunosuppression
|
|
CA2669686A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Pharmacopeia, Llc |
7-substituted purine derivatives for immunosuppression
|
|
KR101591533B1
(ko)
|
2007-05-29 |
2016-02-03 |
노파르티스 아게 |
항-ｉｌ-1-베타 치료법에 대한 신규 적응증
|
|
TWI444379B
(zh)
|
2007-06-29 |
2014-07-11 |
Sunesis Pharmaceuticals Inc |
有用於作為Ｒａｆ激酶抑制劑之化合物
|
|
AU2008273017C1
(en)
|
2007-06-29 |
2014-02-13 |
Millennium Pharmaceuticals, Inc. |
Heterocyclic compounds useful as Raf kinase inhibitors
|
|
US8415358B2
(en)
|
2007-09-17 |
2013-04-09 |
Neurosearch A/S |
Pyrazine derivatives and their use as potassium channel modulators
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
EP2214486A4
(en)
*
|
2007-10-19 |
2011-03-09 |
Avila Therapeutics Inc |
HETEROARYL COMPOUNDS AND ITS USES
|
|
EP2209916B1
(en)
|
2007-11-08 |
2011-12-21 |
Novartis AG |
Gene expression signatures for chronic/sclerosing allograft nephropathy
|
|
CN101932583A
(zh)
*
|
2007-12-19 |
2010-12-29 |
沃泰克斯药物股份有限公司 |
用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
CA2728893C
(en)
|
2008-04-16 |
2017-03-14 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk protein kinase
|
|
MX2010011463A
(es)
|
2008-04-16 |
2011-06-03 |
Portola Pharm Inc |
2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
|
|
JP2011518219A
(ja)
|
2008-04-22 |
2011-06-23 |
ポートラ ファーマシューティカルズ， インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
|
MX2010012080A
(es)
*
|
2008-05-05 |
2011-04-11 |
Univ Winthrop Hospital |
Metodo para mejorar el perfil de riesgo cardiovascular de los inhibidores de cox.
|
|
RU2560153C2
(ru)
|
2008-06-20 |
2015-08-20 |
Дженентек, Инк. |
Триазолпиридиновые соединения, ингибирующие jak, и способы
|
|
AU2009259867A1
(en)
|
2008-06-20 |
2009-12-23 |
Genentech, Inc. |
Triazolopyridine JAK inhibitor compounds and methods
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
SG10201510696RA
(en)
|
2008-06-27 |
2016-01-28 |
Celgene Avilomics Res Inc |
Heteroaryl compounds and uses thereof
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
JP5918693B2
(ja)
|
2009-05-05 |
2016-05-18 |
ダナ ファーバー キャンサー インスティテュート インコーポレイテッド |
Ｅｇｆｒ阻害剤及び疾患の治療方法
|
|
US9752191B2
(en)
|
2009-07-09 |
2017-09-05 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
EP2566867A1
(en)
*
|
2010-04-30 |
2013-03-13 |
Cellzome Limited |
Pyrazole compounds as jak inhibitors
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
MY160734A
(en)
|
2010-08-10 |
2017-03-15 |
Celgene Avilomics Res Inc |
Besylate salt of a btk inhibitor
|
|
NZ710636A
(en)
|
2010-11-01 |
2017-02-24 |
Celgene Avilomics Res Inc |
Heterocyclic compounds and uses thereof
|
|
AU2011323484B2
(en)
|
2010-11-01 |
2016-10-06 |
Portola Pharmaceuticals, Inc. |
Benzamides and nicotinamides as Syk modulators
|
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
|
WO2012061428A2
(en)
|
2010-11-01 |
2012-05-10 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
US20130317029A1
(en)
|
2010-11-01 |
2013-11-28 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
|
US8889684B2
(en)
*
|
2011-02-02 |
2014-11-18 |
Boehringer Ingelheim International Gmbh |
Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
|
|
CA2831582C
(en)
|
2011-03-28 |
2019-01-08 |
Mei Pharma, Inc. |
(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
AU2012255792A1
(en)
|
2011-05-17 |
2013-11-07 |
Principia Biopharma Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
|
CN102267980B
(zh)
*
|
2011-06-04 |
2012-11-21 |
山西大学 |
2，6-二苯并咪唑基吡啶的制备方法
|
|
AU2012277391A1
(en)
|
2011-06-27 |
2013-12-19 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
WO2013008095A1
(en)
|
2011-07-08 |
2013-01-17 |
Novartis Ag |
Novel pyrrolo pyrimidine derivatives
|
|
WO2013057711A1
(en)
|
2011-10-21 |
2013-04-25 |
Novartis Ag |
Quinazoline derivatives as pi3k modulators
|
|
CA2853498A1
(en)
|
2011-10-28 |
2013-05-02 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
SG11201402570QA
(en)
|
2011-11-23 |
2014-06-27 |
Portola Pharm Inc |
Pyrazine kinase inhibitors
|
|
AP2014007680A0
(en)
|
2011-12-02 |
2014-06-30 |
Novartis Ag |
Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
|
|
CA2857302C
(en)
|
2011-12-15 |
2020-08-25 |
Novartis Ag |
Use of inhibitors of the activity or function of pi3k
|
|
IN2014CN04174A
(enExample)
|
2011-12-22 |
2015-09-04 |
Novartis Ag |
|
|
US20150148377A1
(en)
|
2011-12-22 |
2015-05-28 |
Novartis Ag |
Quinoline Derivatives
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
|
JP6353788B2
(ja)
|
2012-01-13 |
2018-07-04 |
エイシア バイオサイエンシーズ インコーポレイテッド |
抗がん剤としての複素環式化合物およびその使用
|
|
US9464089B2
(en)
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
SMT201800571T1
(it)
|
2012-03-15 |
2019-01-11 |
Celgene Car Llc |
Sali di un inibitore di chinasi del recettore del fattore di crescita dell’epidermide
|
|
BR112014022789B1
(pt)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
|
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
|
CA2879570A1
(en)
|
2012-07-24 |
2014-01-30 |
Pharmacyclics, Inc. |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
|
US9573958B2
(en)
|
2012-08-31 |
2017-02-21 |
Principia Biopharma, Inc. |
Benzimidazole derivatives as ITK inhibitors
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
EA035349B1
(ru)
|
2012-11-21 |
2020-05-29 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
EP3007689B1
(en)
|
2013-01-10 |
2018-03-07 |
Pulmokine, Inc. |
Non-selective kinase inhibitors
|
|
MA38287B1
(fr)
|
2013-01-23 |
2018-08-31 |
Astrazeneca Ab |
Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
|
|
US9561228B2
(en)
|
2013-02-08 |
2017-02-07 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
AU2014287016B2
(en)
|
2013-07-11 |
2018-11-01 |
Acea Biosciences Inc. |
Pyrimidine derivatives as kinase inhibitors
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
WO2015030847A1
(en)
|
2013-08-30 |
2015-03-05 |
Ptc Therapeutics, Inc. |
Substituted pyrimidine bmi-1 inhibitors
|
|
WO2015179773A1
(en)
|
2014-05-22 |
2015-11-26 |
The Scripps Research Institute |
Tissue molecular signatures of kidney transplant rejections
|
|
KR20160060100A
(ko)
|
2013-09-22 |
2016-05-27 |
칼리토르 사이언시즈, 엘엘씨 |
치환된 아미노피리미딘 화합물 및 이용 방법
|
|
EP3054937B1
(en)
|
2013-10-11 |
2023-07-26 |
Pulmokine, Inc. |
Spray dry formulations
|
|
WO2015076800A1
(en)
*
|
2013-11-21 |
2015-05-28 |
Ptc Therapeutics, Inc. |
Substituted pyridine and pyrazine bmi-1 inhibitors
|
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CN106458980A
(zh)
|
2014-04-24 |
2017-02-22 |
诺华股份有限公司 |
作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
|
|
BR112016024533A8
(pt)
|
2014-04-24 |
2021-03-30 |
Novartis Ag |
derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
|
|
KR20160141856A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
|
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
|
TWI679205B
(zh)
|
2014-09-02 |
2019-12-11 |
日商日本新藥股份有限公司 |
吡唑并噻唑化合物及醫藥
|
|
GB201518456D0
(en)
*
|
2015-10-19 |
2015-12-02 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
|
|
TWI712604B
(zh)
|
2016-03-01 |
2020-12-11 |
日商日本新藥股份有限公司 |
具jak抑制作用之化合物之結晶
|
|
EA202092442A3
(ru)
|
2016-06-07 |
2021-08-31 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
|
KR20230093341A
(ko)
|
2016-10-27 |
2023-06-27 |
풀모킨 인코포레이티드 |
폐고혈압을 치료하기 위한 병용 요법
|
|
AU2018239542C1
(en)
|
2017-03-23 |
2021-02-11 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as SHP2 inhibitors
|
|
AU2017408099A1
(en)
|
2017-04-07 |
2019-11-07 |
ACEA Therapeutics, Inc. |
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
|
|
CA3063976A1
(en)
|
2017-05-23 |
2018-11-29 |
Mei Pharma, Inc. |
Combination therapy
|
|
MX2020001727A
(es)
|
2017-08-14 |
2020-03-20 |
Mei Pharma Inc |
Terapia de combinacion.
|
|
EP3697777A1
(en)
|
2017-10-19 |
2020-08-26 |
eFFECTOR Therapeutics, Inc. |
Benzimidazole-indole inhibitors of mnk1 and mnk2
|
|
CA3078267C
(en)
|
2017-10-27 |
2024-06-18 |
Shanghai Yao Yuan Biotechnology Co., Ltd. |
Compositions and methods of modulating the immune response by activating alpha protein kinase 1
|
|
CA3083040A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
AU2019340402B2
(en)
|
2018-08-17 |
2025-04-03 |
Ptc Therapeutics, Inc. |
Method for treating pancreatic cancer
|
|
US20210393623A1
(en)
|
2018-09-26 |
2021-12-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
|
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
WO2020212395A1
(en)
|
2019-04-16 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
|
CN121471151A
(zh)
|
2019-05-23 |
2026-02-06 |
诺华股份有限公司 |
Btk抑制剂的晶型
|
|
US12441707B2
(en)
|
2019-12-30 |
2025-10-14 |
Tyra Biosciences, Inc. |
Indazole compounds
|
|
CN116490201A
(zh)
*
|
2020-07-02 |
2023-07-25 |
布里奇恩生物科学公司 |
Yap/taz-tead肿瘤蛋白的抑制剂，其合成和用途
|
|
CN112358468B
(zh)
*
|
2020-11-10 |
2022-03-22 |
德州德药制药有限公司 |
一种工业化合成azd9291的方法
|
|
CN112980809B
(zh)
*
|
2021-03-17 |
2023-04-11 |
云南中烟工业有限责任公司 |
一种烟草法尼基焦磷酸合酶基因及其应用
|
|
JP2024544556A
(ja)
*
|
2021-11-12 |
2024-12-03 |
バイオポーラー ヨータン（グァンドン） ファーマシューティカル カンパニー，リミテッド |
Ｄｒａｋ２阻害剤およびその製造方法と使用
|
|
US20250283174A1
(en)
|
2022-05-16 |
2025-09-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
|